• Biomarkers identified or further evaluated in the last five years, up until January 2013. From a background of extensive research on bevacizumab (Avastin®) and VEGF-related biomarkers, the most important findings have been identified for their significance and value to patients and in designing clinical trials
• Covering more than ten cancers including colorectal, ovarian, renal, breast, pancreatic, prostate, lung and liver cancers
• Findings based on clinical trial findings including patient numbers, statistics and RECIST criteria
• Studies indicate drug type associations together with comparative therapies
• Descriptions and explanation of all biomarkers identified (proteins, genotypes, imaging etc)
• Biomarker associations are categorised according to three broad criteria, namely "positive-therapy-indicating" (response, improved response, improved outcome or prognosis), "non-therapy-indicating" (no differences in tumour response, outcome or prognosis) and "negative-therapy-indicating" (adverse events, poor outcome or prognosis).
Executive Summary
Chapter 1: Background (p.18)
1.1 VEGF Inhibition
1.2 Bevacizumab
1.3 Biomarkers
1.4 This Report
Chapter 2 Colorectal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p. 22)
Summary
2.1 Introduction
2.2 Glycoprotein
2.3 Protein
2.4 Protein
2.5 Cells
2.6 Genetic
2.7 Physical
2.8 Genetic
2.9 Protein
2.10 Proteins
2.11 Proteins and Genetic
2.12 Image
2.13 Proteins
2.14 Pro
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |